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This study was conducted to determine if the monoclonal antibody drug infliximab could 
effectively suppress the fibrosis immune response in three-spine stickleback fish.  Successful 
suppression of this response could allow for further study of cestode infection and growth without 
the presence of fibrosis. Infliximab’s efficacy was investigated through conducting two 
intraperitoneal injection experiments and examinations of the fibrosis in the body cavity of the 
euthanized stickleback. We used immune adjuvant alum to induce a fibrosis response without the 
presence of the S. solidus tapeworm parasite. Ultimately, the differences in fibrosis levels between 
the treatment groups that received alum and the groups that received alum+infliximab were not 
statistically significant. These findings suggest that infliximab is not a good candidate for 
attenuating the fibrosis response in three-spine stickleback and other methods of suppressing 
fibrosis to examine cestode growth should be pursued. 
 
Introduction 
 Fibrosis is a pathological response characterized by an accumulation of 
extracellular matrix proteins that plays a major role in a wide variety of diseases in humans. The 
two major purposes of the fibrosis response are host resistance to a pathogen or wound healing. In 
some instances, the fibrosis response leads to an excessive amount of extracellular matrix buildup 
that can cause long-term scarring (Thannickal et al. 2014). The excess formation of connective 
tissue due to fibrosis can result in damage or failure in multiple organs or organ systems. This 
outcome is so common that an estimated 45% of all mortality in the United States involve some 
form of fibrotic disorder (Neary et al. 2015).  
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After infection with a pathogen, the fibrosis response is capable of preventing further 
spread and damage to the host through the formation of fibrotic scars around the infection, although 
this is not possible with every pathogen. Wound healing can also be aided by fibrosis, a fibrotic 
scar could help reduce blood loss and preserve the structural integrity of the organ (Thannickal et 
al. 2014). Organisms that exhibit a fibrosis response need a mechanism to attenuate the fibrotic 
tissue if it accumulates to the point where it could cause damage (Hall et al 2017).  
The mechanism of fibrosis formation for wound healing in humans happens in four broad 
stages: initial injury, hemostasis, regeneration, and remodeling (fibrosis). Once the injury occurs 
in epithelial or endothelial tissue, platelets accumulate to form a protective clot. During 
regeneration, neutrophils and monocytes remove debris, which allows the remodeling process to 
proceed. Multiple types of cytokines recruit fibroblast cells, which produce collagen and other 
extracellular matrix proteins. Epithelial or endothelial cells subsequently transfer to the site of the 
injury and complete wound healing (Wynn 2004). Articles such as Wynn’s are able to go into great 
detail about fibrosis pathogenesis, but much less information is available regarding the 
mechanisms underlying the abnormal deposition of extracellular matrix. This gap in our 
understanding has created a shortage of specific and effective treatments for the harmful forms of 
fibrosis (Neary et al. 2015). 
  The three-spine stickleback, also known as Gasterosteus aculeatus, is a fish that is found 
in the northern hemisphere. They reside in both freshwater and marine habitats that are often 
genetically and physically isolated from one another. Their abundance and phenotypic diversity 
make them a useful model system for the “analysis of evolutionary mechanisms” (Bell & Foster 
1994).  The host-parasite interactions between three-spine stickleback and the tapeworm 
Schistocephalus solidus are of particular interest. Three-spine stickleback serve as an intermediate 
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host for the tapeworm, and infection occurs almost entirely in freshwater populations. As a form 
of defense against S. solidus, some populations of stickleback mount an immune response that 
relies on fibrosis to impede the cestode’s growth. The stickleback’s peritoneal cavity becomes 
riddled with fibrotic tissue in severe cases (Hund et al. 2020 in prep). While this process is capable 
of resisting the tapeworm infection, there are often serious fitness costs for the fish. For example, 
the presence of fibrosis decreases the likelihood of successful reproduction in wild populations 
(De Lisle & Bolnick 2021). Therefore, the fibrosis response must be both swift and reversible in 
order to prevent long-term damage (Hund et al. 2020 in prep).  
 Similar to humans, the pathway and mechanisms of every part of fibrosis formation are not 
fully studied in stickleback. According to a coexpression network analysis of immune related 
genes, resistance to a parasitic infection is influenced by the tapeworm’s survival and the level of 
growth arrest (Lohman et al. 2017). Other studies use a stepwise approach to identify aspects of 
the fibrosis pathway by testing marine, resistant, and susceptible populations with immune 
challenges. All three populations exhibited fibrosis after injection with the immune adjuvant alum, 
but only the resistant population exhibited fibrosis after injection with proteins from the tapeworm. 
The findings of this study suggest that the ability to mount a beneficial fibrosis response after 
infection in the wild is population specific (Hund et al. 2020 in prep). Overall, the molecular 
processes of the fibrosis pathway in stickleback are less clear when compared to our range of 
knowledge for humans.  
Examining the interactions between the stickleback host, the S. solidus parasite, and the 
immune system’s fibrosis response has the potential to inform our understanding of broader 
evolutionary trends in hosts’ response to infection (Hund et al. 2020 in prep). Studies that 
investigate the growth of cestodes within stickleback must consider the interference of fibrosis in 
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their findings if the population is resistant. While there are therapeutic options for 
pharmacologically treating fibrosis in humans, these drugs have little to no available efficacy data 
for stickleback. A drug that is capable of suppressing the fibrosis response for three-spine 
stickleback could help with the design of experiments examining the growth of S. solidus. If it is 
possible to remove the interference of the fibrosis response, studies could then document whether 
or not the growth of S. solidus can continue after drug-induced suppression.  
 The drug infliximab, also known as Remicade, is an anti-TNF alpha monoclonal antibody 
that has been tested in rats and humans to determine if it is capable of suppressing multiple types 
of fibrosis. The FDA originally approved the drug for Crohn’s disease treatment, but it is also 
applicable in conditions such as rheumatoid arthritis (Multum 2020). It eliminates oxygen free 
radicals that are meant to activate crucial cytokines within the fibrosis pathway. Ultimately, this 
results in less overall harm to the tissue because of excessive angiogenesis (Altintas et al. 2016). 
A study of bleomycin-induced lung fibrosis in rats concluded that infliximab was capable of 
preventing this type of fibrosis in rats. The study came to this conclusion by measuring levels of 
cytokines such as TNF-alpha and interleukin 6 that play a role in fibrosis activation. The 
histological findings also supported this because stained tissue from the infliximab treated rats 
showed less inflammation and excess fibrosis (Altintas et al. 2016). An additional study tests 
infliximab’s usefulness in treating human pulmonary fibrosis. Four patients with existing severe 
pulmonary fibrosis received multiple temporally spaced infliximab treatments, and the patients’ 
symptoms were consistent through the course of the study. The authors posit that infliximab could 
help stabilize this damaging form of fibrosis, but extensive clinical trials must support these initial 
findings before infliximab can be considered a good therapy for pulmonary fibrosis (Antoniou et 
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al. 2007). Infliximab also exists in a liquid form that makes it simple to administer intraperitoneally 
(Multum 2020).  
Given the findings of these studies in rats and humans, we chose infliximab as the drug for 
a pilot study intended to determine if this drug is capable of partially or completely suppressing 
fibrosis in three-spine stickleback. The immune adjuvant alum can effectively activate the fibrosis 
response in both susceptible and resistant populations of stickleback, and it often serves as a 
method of fibrosis activation without the need for infecting fish in an experimental environment 
(Kool et al. 2012) We hypothesized that infliximab could interfere with the fibrosis pathway and 
ultimately attenuate the alum-induced fibrosis response.  Because alum is administered 
intraperitoneally in stickleback, we chose a series of injection experiments as the experimental 
strategy for testing infliximab’s functioning. 
 
Methods 
Injection Experiment One 
The first experiment occurred in January 2021 using 39 three-spine stickleback fish from 
Roselle Lake. It is a freshwater lake located on Vancouver Island in British Columbia, Canada, 
and its population of three-spine stickleback is resistant to S. solidus infection through its strong 
fibrosis response. We chose Roselle stickleback for this experiment because they exhibit fibrosis 
after intraperitoneal injection with alum (Hund et al. 2020 in prep). Collection of Roselle fish 
occurred in the summer of 2019 and were used to create lab-reared descendants in the animal care 
facility at the University of Connecticut. We collected these Roselle descendants from vivarium 
tanks in the animal care facility for use in the injection experiments. We then gave one of four 
treatments by intraperitoneal injection. The first group served as the control treatment, so it 
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received 20 μ1 of 1X phosphate buffered saline (PBS). The second group was the alum treatment, 
which received 10 μ1 alum (2% Alumax Phosphate, OZ Bioscience) and 10 μ1 PBS. We created 
this group so that we could directly compare the fibrosis levels of the alum treatment and the alum+ 
infliximab treatment to determine if the infliximab could produce the hypothesized decrease in 
fibrosis. The third group was the infliximab treatment, these fish received 10 μl infliximab (TNF 
Alpha antibody cA2, Bio-Rad) and 10 μ1 PBS. This group is not useful for determining the drug’s 
efficacy in reducing fibrosis because it did not receive the alum irritant, but it was necessary to 
include in the first experiment to ensure that infliximab was not causing any fibrosis in the 
stickleback on its own. The last group was the alum+infliximab treatment, they received 10 μ1 
alum and 10 μl infliximab to test if infliximab could attenuate alum-induced fibrosis. The control, 
alum, and infliximab treatment groups each had 10 samples, and the alum+infliximab group had 
9. We adapted the injection protocol from the novel procedure described in Hund et al. (Hund et 
al. 2020 in prep).  
The solutions for each treatment were prepared and loaded into insulin syringes in a sterile 
culture hood. The fish were anesthetized with diluted MS-222 and kept on a wet sponge prior to 
injection. Each fish also received an elastomer dye injection on the top of its head between the 
eyes to differentiate treatment groups. Injections were given into the peritoneal cavity at an angle 
parallel to the fish’s body to prevent organ puncture. As soon as the injection was complete, the 
fish were placed in an aerated recovery tank. Injected fish were distributed into five long-term 
tanks and each tank had one or two samples from each group. The mortality rate was 15% (6 out 
of 39), four of these deaths occurred multiple days after initial injection. One sample died in the 
control, alum, and infliximab treatments, and three died in the alum+infliximab group. We 
excluded dead fish from all data collection. 
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 After 10 days, we euthanized all remaining fish using a lethal dose of MS-222 and assessed 
their fibrosis by examining the body cavity. A 0-4 scale was used to visually quantify fibrosis: 0 
(no fibrosis), 1 (organs are not moving freely), 2 (organs are adhering together), 3 (organs adhering 
together and to the peritoneal wall), 4 (severe fibrosis, cannot open peritoneal cavity). The protocol 
was IACUC approved (protocol A18-008). 
 
Injection Experiment Two 
The second experiment occurred in April 2021 using 36 three-spine stickleback from 
Gosling Lake. This lake is also on Vancouver Island in British Columbia, but the stickleback 
population there is genetically isolated from the Roselle population. Gosling stickleback also 
exhibit fibrosis, but they are more susceptible to cestode infection (Lohman et al. 2017). Gosling 
fish were collected in the summer of 2019 and subsequently used to breed lab-reared descendants 
in the animal care facility at the University of Connecticut. We injected these fish that originated 
in the Gosling lake due to availability constraints for Roselle fish. The injection procedure was 
performed the same way as the first experiment, but we only used two treatment groups. The 
previous experiment showed that the alum treatment was inducing fibrosis as expected and the 
infliximab treatment was not causing fibrosis compared to the saline control. Given these findings, 
we made these changes to increase the sample size for each group and to continue investigating if 
there were any statistically significant changes in fibrosis levels. The treatment groups are as 
follows: 
A) 10 μ1 alum + 10 μ1 PBS (alum treatment)  
B) 10 μ1 alum + 15 μl infliximab (alum+infliximab treatment) 
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The mortality rate was 25% (9 out of 36), and the majority of the deaths occurred a few days 
after the injections. The alum treatment had 4 deaths and the alum+infliximab group had 5 deaths. 
After 10 days, all of the remaining fish were euthanized.  
 
Analysis of Injection Experiment Results 
For both experiments, two-sample Mann-Whitney U tests assuming unequal variances 
were performed using Microsoft Excel to determine if there were any statistically significant 
differences in fibrosis between treatment groups. Mann-Whitney U tests are appropriate to analyze 
this data because fibrosis level is an ordinal value. We also used Excel to determine descriptive 
statistics such as median and standard error for each treatment group. For the first experiment, we 
analyzed three sets of data in the U test: 
A) Control vs. alum to determine the efficacy of alum  
B) Control vs. infliximab to determine the effects of infliximab without alum 
C) Alum vs. alum+infliximab to determine the effects of infliximab after alum injection  
After the second experiment we only compared the alum and the alum+infliximab groups. We 
then used R Studio to create violin plots to visualize the distribution of fibrosis level within 









In experiment one for the control and alum groups, the medians were 0 and 2 respectively, 
U= 13.5, n1 = n2 = 9, P < 0.05 two-tailed. The difference in median fibrosis is therefore statistically 
significant, so the alum was confirmed to be effective. For both the control and infliximab groups, 
none of the stickleback exhibited fibrosis (value of 0), so the infliximab likely did not cause an 
increase in fibrosis in this experiment (U=40.5, n1 = n2 = 9, P >0.05 two tail). The alum and 
alum+infliximab groups had medians of 2 and 1. The hypothesized outcome was a decrease in 
fibrosis in the alum+infliximab group, but according to the U-test, this difference is not statistically 
significant (U=22, n1 = 9, n2 = 6, P >0.05 two tail). The violin plot below visually represents the 















control   infliximab   
    
Mean 0 Mean 0 
Standard Error 0 Standard Error 0 
Median 0 Median 0 
Mode 0 Mode 0 
Standard Deviation 0 
Standard 
Deviation 0 
Sample Variance 0 Sample Variance 0 
 
control   alum   
    
Mean 0 Mean 1.33333333 
Standard Error 0 Standard Error 0.372678 
Median 0 Median 2 
Mode 0 Mode 2 
Standard Deviation 0 
Standard 
Deviation 1.11803399 
Sample Variance 0 Sample Variance 1.25 
 
alum   alum+infliximab   
    
Mean 1.333333333 Mean 1 
Standard Error 0.372677996 Standard Error 0.36514837 
Median 2 Median 1 
Mode 2 Mode 1 
Standard Deviation 1.118033989 
Standard 
Deviation 0.89442719 
Sample Variance 1.25 Sample Variance 0.8 
 




Figure 1 Violin plot showing the distribution of samples within the control, alum, infliximab, 
and alum+infliximab treatment. Mean and standard deviation are shown. The control, alum, and 












In the second experiment, the alum+infliximab group had a median of 1, which is higher 
than the 0 median value for the alum group. This result contradicts the original hypothesis, but this 
difference is ultimately not statistically significant (U=63, n1 = 14, n2 = 13, P >0.05 two tail). The 







alum   alum+infliximab   
    
Mean 0.5 Mean 1 
Standard Error 0.17383837 Standard Error 0.25318484 
Median 0 Median 1 





Sample Variance 0.42307692 Sample Variance 0.83333333 
 




Figure 2 Violin plot showing the distribution of samples within the alum and alum+infliximab 
treatment groups. Mean and standard deviation are shown. The alum group had 14 samples, and 










 The lack of a statistically significant change in fibrosis between the infliximab absent and 
infliximab present groups suggests that infliximab administered at these dosages is not an effective 
fibrosis suppressant in stickleback from Roselle or Gosling lake. The findings from both 
experiments support this conclusion. Because of the lack of knowledge regarding the mechanism 
of the fibrosis pathway in stickleback, there are multiple potential reasons why infliximab was not 
an effective suppressant. Some of this fish species’ genes have been identified as targets in fibrosis, 
but the ultimate pathway is not known definitively (Fuess et al. 2020). Because infliximab is a 
human anti-TNF alpha inhibitor, it is likely that this drug does not chemically interfere with the 
fibrosis pathway in stickleback (Cerner 2020). Due to the genetic isolation of many populations of 
stickleback, different populations can significantly vary in their genetic diversity when it comes to 
their immune responses (Kurtz et al. 2004, Bell & Foster 1994). Roselle fish, which were used in 
the first experiment, have been observed having higher fibrosis than Gosling fish in response to 
alum injection (Hund et al. 2020 in prep). The strength of the fibrosis response in a given 
population could potentially affect the visual observation of the fibrosis in the peritoneal cavity 
after dissection.  
The infliximab dose given to the Roselle fish in the first experiment was 10 μ1, which was 
chosen due to the dose given in humans, which is 5 mg/kg (Cerner 2020). Since the stickleback 
from Roselle and Gosling typically have a mass of 2 to 3 grams, a dose of 10 μ1 (5 μ1/gram body 
mass) was chosen for the sake of simplicity when loading the treatments into the needles. When 
the infliximab was not effective during the first experiment, a dose of 15 μ1 was given to the 
Gosling fish to test if a higher dose could produce a statistically significant difference in the 
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treatments. There was no evidence that the infliximab was the cause of mortality for the Roselle 
fish because the deaths were similarly distributed among all four treatment groups, so a higher 
dose was considered to be a reasonable modification to the experimental design. Humans receiving 
this drug to suppress fibrosis are on it for a prolonged period of time, sometimes ten weeks (Cerner 
2020). It is administered intravenously every two weeks, but this strategy to investigate infliximab 
effectiveness was not chosen since alum is capable of inducing the fibrosis response fairly quickly 
(Kool et al. 2012). 
 Multiple factors potentially impacted the validity of these results. First, due to this being a 
pilot study, the sample size for the groups receiving only alum or alum+infliximab ranged from 6 
to 14. However, since this experiment was conducted twice and the sample sizes were larger in the 
second experiment, this does not mean that increasing the number of samples would significantly 
change the results. In addition, potential infection, organ puncture, or insufficient oxygen intake 
after the injection are likely causes of death for the stickleback that did not survive the full ten 
days.  
 
Conclusion and Future Approaches 
 Due to infliximab’s lack of efficacy in this experiment, it cannot be a good candidate for 
further studies regarding drug-induced suppression. One approach that would have greater 
potential for fibrosis suppression is interfering with the transcription factor PU.1. Empirical data 
shows that the heterocyclic diamidine drug DB1976 is able to significantly reverse fibrosis 
formation in mice through its targeting of the SPI1 gene, which produces PU.1 (Wohlfahrt et al. 
2019).  Sticklebacks have the SPI1 gene, so pharmacological interference with PU.1 could serve 
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